Dr. Juergen Reess
Juergen Reess, MD is the Chief Medical Officer at SciRhom and Chief Executive Officer at Mogling Bio with over 20 years of experience in operative and strategic clinical development.
Juergen has extensive experience leading a wide range of projects. He supervised the development, approval, and launch of numerous blockbuster therapies for autoimmune diseases, interstitial lung diseases, central nervous system disorders, and cancer, meeting milestones in nearly 100 projects across several therapy areas.
He approved and launched various products globally, including MIRAPEX/Sifrol IR and SR tablets for early/advanced Parkinson‘s disease and Restless Leg Syndrome, and Giotrif/ Afatinib in non-small cell lung cancer.
Read Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study—the PRELUDE study and An item response analysis of the international restless legs syndrome study group rating scale for restless legs syndrome.
At Mogling Bio since 2022, Juergen is developing novel pharmacological approaches to rejuvenate old stem cells. He is pursuing novel pharmacological approaches to inhibit the elevated activity of Cdc42 in hematopoietic stem cells (HSCs). Targeting the activity of Cdc42 will re-order and rejuvenate the function of old HSCs.
This approach could ameliorate aging-associated diseases like multiple myeloma and myelodysplasia syndromes and restore the aging-associated decline in the function of the immune system. Mogling Bio received a grant funding round of $300K on September 23, 2024, with participation from HHS and Kizoo.
Read Kizoo Technology Capital GmbH. (10/26/22). “Press Release: Kizoo Invests in Rejuvenation Startup MoglingBio”. Berlin & Ulm and MoglingBio wins further funding from Kizoo to accelerate hematopoietic stem cell and immune system rejuvenation.
Juergen has been an Independent Pharma Consultant since 2021 offering his lifelong expertise in Project Management, as Chief Medical Officer, on Clinical Development, and Leadership.
As the CMO at SciRhom, a pioneering biotech enterprise with the vision to translate advanced scientific findings into game-changing therapies for autoimmune diseases, Juergen is building on a detailed understanding of how a major cell-surface protease controls inflammation. SciRhom has worked extensively to develop first-in-class humanized antibodies against iRhom2, which controls the enzyme TACE, a key node in several disease-causing signaling pathways.
Previously, he was Managing Director at Cellerys, Scientific Advisory Board Member at OVID Clinic Berlin, and Clinical Consultant at Amylyx Pharmaceutical.
Before that, he was Corporate Senior Vice President of International Project Management at Boehringer Ingelheim Human Pharma for more than 20 years. Read After 20 years, Boehringer vet hits the exit to become CEO at autoimmune biotech SciRhom.
Juergen earned his MD in 1989 from Ulm University with his thesis about Pharmaco EEG Spectral Analysis titled Studie mit Langzeitmedikation zur Wirkung von Haloperidol und der Kombination von Haloperidol und Biperiden auf den EEG-Frequenzinhalt von gesunden Normalpersonen vor und während einer Willkürbewegung. Between 1989 and 1994, he was Member of the Neurological Clinic at Ulm University, and he finalized this period with an exam as a board-certified Neurologist.
In 1994, he became a Clinical Research Physician at Sanofi Winthrop where he had medical responsibility for the CAPRIE (Clopidogrel vs Aspirin) study in Germany and Austria.
Between 1996 and 2000, Juergen was the Vice Director and Doctor at the Neurological Clinic Dietenbronn GmbH, where he had responsibility for a ward with 30 beds with all kinds of different neurological diseases, focusing on multiple sclerosis and cerebrovascular diseases.
Juergen attended the CELforPharma’s Health Economics for Non-Health-Economists with Lieven Annemans in 2016. He also took The Pharma Forecasting Course at CELforPharma in 2014, the BI Global Strategic Leadership Program at INSEAD in 2013, and the General Management Seminar for Executives at St. Galler Business School in 2007.
He was a Member of the Board of Directors at Cyxone between 2023 and 2025. Cyxone is a clinical-stage biotech company specializing in the development of transformative therapies against autoimmune and autoinflammatory diseases. He was also a Member of the Scientific Advisory Board for Pivotal Investment Fund (Nan Fung Life Sciences) concluded in December 2024 and having started in September 2021.
Juergen also presented at the Rejuvenation Startup Summit 2024, where he spoke of developing approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.
Visit his LinkedIn profile and his ResearchGate page. Follow him on Facebook, Instagram, Crunchbase, Market Screener, and Twitter.